Plus Therapeutics announces oral presentation highlighting Reyobiq(TM) clinical and translational data demonstrating favorable safety, survival, and emerging immunomodulation in leptomeningeal metastases

Published: 2026-05-08 08:03:07 ET PSTV

Published on 05/08/2026 at 08:03 am EDT